Opendata, web and dolomites

TRIPLECON

Triple negative breast cancer control through synergistic inhibition of EGFR and CDK9 signaling

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRIPLECON project word cloud

Explore the words cloud of the TRIPLECON project. It provides you a very rough idea of what is the project "TRIPLECON" about.

disproportionally    clinic    cancer    pdx    express    concomitantly    proliferation    attempted    synergistic    treat    signaling    accounting    mainstay    unsatisfactory    outcomes    explore    kinase    bc    treatment    translate    inhibit    poor    targetable    tnbc    lines    cell    patients    disease    80    15    dual    inhibitor    breast    instance    owing    causing    strategy    single    stalling    er    synergized    combination    chemotherapies    proof    benefit    block    cyclin    dysregulated    poc    forms    family    triple    grant    cytotoxic    approved    compensatory    drive    revealed    strikingly    patient    successful    erc    overexpressed    clinical    cdk9    egfr    drug    negative    ongoing    mouse    therapy    xenograft    vivo    molecular    preliminary    receptors    aggressive    benefiting    lapatinib    combinatorial    striving    giving    pharmacological    models    receptor    resistance    pr    her2    epidermal    envisage    death    322737    intrinsic    trials    agent    therapies    dependent    clinically    20    safe   

Project "TRIPLECON" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 90˙075.00
2    UNIVERSITEIT LEIDEN NL (LEIDEN) participant 59˙925.00

Map

 Project objective

'Triple negative breast cancer (TNBC) is an aggressive disease, accounting for 15-20% of breast cancer cases, but disproportionally causing breast cancer-related death. TNBC does not express the targetable receptors ER, PR, and HER2 that are known to drive other forms of breast cancer. Mainstay practice for TNBC in the clinic is to treat with non-targeted cytotoxic chemotherapies. Long-term outcomes are however still poor, most likely owing to intrinsic drug resistance. Clinical trials have attempted to explore molecular targeted therapies to block dysregulated growth factor receptors in TNBC, for instance, epidermal growth factor receptor (EGFR), as it is overexpressed in ~80% of TNBC. Yet, giving the long-standing availability of clinically approved EGFR-targeted therapies, such as lapatinib, the clinical benefit of single agent therapy is unsatisfactory, owing to the compensatory dysregulated signaling pathways. In our ongoing ERC – Advanced Grant Triple-BC (#322737) we are striving to explore combinatorial molecular targeted therapies to concomitantly block the identified dysregulated signaling pathways. Our preliminary work revealed that an inhibitor targeting cyclin-dependent kinase 9 (CDK9) strikingly synergized with targeting EGFR receptor family signaling to inhibit cell proliferation of TNBC cell lines. The overall goal of this PoC project is to exploit this novel finding and provide proof-of-concept evidence that stalling CDK9 signaling may enable successful targeted combination therapy in TNBC. Therefore, the specific objective is to assess the pharmacological response of dual EGFR-CDK9 targeting in TNBC patient-derived xenograft (PDX) mouse models in vivo. We envisage that this PoC project will translate our identified successful synergistic treatment into an effective future novel and safe combinatorial targeting strategy benefiting TNBC patients.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIPLECON" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRIPLECON" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

TroyCAN (2020)

Redefining the esophageal stem cell niche – towards targeting of squamous cell carcinoma

Read More